LogicBio Therapeutics, Inc (LOGC)

Etorro trading 970x250
LogicBio Therapeutics, Inc (LOGC) Logo

About LogicBio Therapeutics, Inc

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient’s genome to provide a therapeutic effect. The company’s lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. It has a collaboration with Children’s Medical Research Institute to develop new viral vectors; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. Address: 65 Hayden Avenue, Lexington, MA, United States, 02421

LogicBio Therapeutics, Inc News and around…

Latest news about LogicBio Therapeutics, Inc (LOGC) common stock and company :

Looking Into LogicBio Therapeutics's Return On Capital Employed
15 Nov, 2021 FinancialContent

According to data from Benzinga Pro, during Q3, LogicBio Therapeutics's (NASDAQ:LOGC) reported sales totaled $2.12 million. Despite a ...

LogicBio Therapeutics (NASDAQ:LOGC) investors are sitting on a loss of 74% if they invested three years ago
15 Nov, 2021 Yahoo! Finance

As every investor would know, not every swing hits the sweet spot. But really bad investments should be rare. So spare...

LogicBio Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones
15 Nov, 2021 Yahoo! Finance

LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today reported financial results for the third quarter ended September 30, 2021 and highlighted recent corporate milestones.

LogicBio Therapeutics to Participate in Upcoming Investor Conferences
11 Nov, 2021 Yahoo! Finance

LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will participate at the following upcoming investor conferences:

Will LogicBio Therapeutics (LOGC) Report Negative Q3 Earnings? What You Should Know
01 Nov, 2021 Yahoo! Finance

LogicBio Therapeutics (LOGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Predict 13% Upside For The Holdings of VXF
22 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Extended Market ETF (VXF), we found that the implied analyst target price for the ETF based upon its underlying holdings is $219.26 per unit.

LogicBio Therapeutics Announces Successful Repopulation of Diseased Livers in Mice with Healthy Corrected Hepatocytes in Two New Indications Using GeneRide™ Genome Editing Technology
21 Oct, 2021 Yahoo! Finance

LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today is slated to present new preclinical data on its GeneRide™ platform at the European Society of Gene and Cell Therapy (ESGCT) Virtual Congress 2021, taking place October 19-22, 2021. The newly presented preclinical data further validate previous research in methylmalonic acidemia (MMA) and highlight selective advantage, a key feature of the GeneRide technology, in two additional indications characterized b

LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children
18 Oct, 2021 Yahoo! Finance

LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced clinical trial results demonstrating the first-ever in vivo genome editing in children. Early data from the company's Phase 1/2 SUNRISE clinical trial showed measurable levels of albumin-2A, a technology-related biomarker indicating site-specific gene insertion and protein expression. The SUNRISE trial is evaluating the safety, tolerability and preliminary efficacy of LB-001, the company's inves

LogicBio Therapeutics to Present New GeneRide™ Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
12 Oct, 2021 Yahoo! Finance

LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that it was selected to present new data from the company's GeneRide™ platform in a plenary oral presentation and three poster presentations at the upcoming European Society of Gene and Cell Therapy (ESGCT) Virtual Congress 2021, to be held from October 19-22, 2021.

LogicBio Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
24 Sep, 2021 Yahoo! Finance

LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that president and chief executive officer, Fred Chereau, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 8:00 a.m. ET.

Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?
14 Sep, 2021 Yahoo! Finance

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

LogicBio Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
10 Sep, 2021 Yahoo! Finance

LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that president and chief executive officer Fred Chereau will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021. The on-demand presentation will be available at 7:00 a.m. ET on Monday, September 13, 2021.

How The Parts Add Up: ITOT Targets $112
19 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core S&P Total US.

LogicBio Therapeutics (LOGC) Reports Q2 Loss, Lags Revenue Estimates
09 Aug, 2021 Yahoo! Finance

LogicBio Therapeutics (LOGC) delivered earnings and revenue surprises of -32.00% and -83.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

LogicBio Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones
09 Aug, 2021 Yahoo! Finance

LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today reported financial results for the second quarter ended June 30, 2021 and highlighted recent corporate milestones.

12 Health Care Stocks Moving In Monday's Pre-Market Session
19 Jul, 2021 FinancialContent

Gainers NRX Pharmaceuticals (NASDAQ:NRXP) stock moved upwards by 67.6% to $14.28 during Monday's pre-market session. ...

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

What Type Of Shareholders Make Up LogicBio Therapeutics, Inc.'s (NASDAQ:LOGC) Share Registry?
16 Jul, 2021 Yahoo! Finance

Every investor in LogicBio Therapeutics, Inc. ( NASDAQ:LOGC ) should be aware of the most powerful shareholder groups...

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
09 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021
08 Jul, 2021 Yahoo! Finance

LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that Frederic Chereau, chief executive officer of LogicBio, will participate in a virtual panel discussion entitled "Delivery and Durability of Genetic Medicines" at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 10:00 a.m. ET.

We Did The Math VXF Can Go To $209
02 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Extended Market ETF (VXF), we found that the implied analyst target price for the ETF based upon its underlying holdings is $208.60 per unit.

Is LogicBio Therapeutics, Inc. (LOGC) A Good Stock To Buy?
28 Jun, 2021 Yahoo! Finance

In this article we will analyze whether LogicBio Therapeutics, Inc. (NASDAQ:LOGC) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead […]

The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway
23 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Friday
18 Jun, 2021 FinancialContent

Before 10 a.m. ET on Friday, 29 companies hit new 52-week lows. Noteables: The largest company in terms of market cap ...

Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2021
07 Jun, 2021 FinancialContent

Upgrades Deutsche Bank upgraded the previous rating for Marriott Vacations Worldwide Corp (NYSE:VAC) from Hold to Buy. ...

A Peek Into The Markets: US Stock Futures Edge Lower Following Friday's Surge
07 Jun, 2021 FinancialContent

Pre-open movers U.S. stock futures traded slightly lower in early pre-market trade after the Nasdaq jumped 200 points in the previous ...

12 Health Care Stocks Moving In Wednesday's After-Market Session
02 Jun, 2021 FinancialContent

Gainers Tilray (NASDAQ:TLRY) shares increased by 4.05% to $19.77 during Wednesday's after-market session. This security traded at a ...

LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia
02 Jun, 2021 Yahoo! Finance

LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that the first patient has been dosed with LB-001, the Company's investigational single-administration gene editing therapy based on its proprietary GeneRide™ platform, in the SUNRISE Phase 1/2 clinical trial in pediatric patients with methylmalonic acidemia (MMA). The child re

Analysts Anticipate 22% Gains Ahead For VTWG
01 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $264.25 per unit.

LogicBio Therapeutics, Inc (LOGC) is a NASDAQ Common Stock listed in , ,

970x250